Search

Bedaquiline

[A261856,A261861] It is the first drug that was approved in the last 40 years by the FDA for TB unresponsive to current treatments on the market. … [A261861] Bedaquiline was approved by the FDA on December 28, 2012, to treat pulmonary MDR-TB, following favorable results in multiple pre-clinical and clinical studies.

Inavolisib

Inavolisib is an inhibitor of PI3Kα that was approved by the FDA in October 2024 for the treatment of certain patients with advanced breast cancers.

Chromium

Chromium chloride is available as an intravenous injection for use as a supplement to intravenous solutions given for total parenteral nutrition (TPN) [FDA Label].

Respiratory syncytial virus vaccine, adjuvanted

[L46347] On May 3, 2023, it was approved by the FDA for immunization against lower respiratory tract disease (LRTD) as the first respiratory syncytial virus (RSV) vaccine approved in the United States

Pipendoxifene

ER modulator, ERA-923(Pipendoxifene) is a estrogen receptor modulator being evaluated for the treatment of breast cancer.

Oxilofrine

Oxilofrine is used in combination with DB11609 as an antitussive. It is currently marketed in Canada by Valeant under the tradename Cophylac.

Sodium borate

Sirolimus

[A242412] In May 2015, the FDA approved sirolimus for the treatment of patients with lymphangioleiomyomatosis. … [A1320] Sirolimus was first approved by the FDA in 1999 for the prophylaxis of organ rejection in patients aged 13 years and older receiving renal transplants.

Sodium phosphate, monobasic, unspecified form

Osimertinib

[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the T790M mutation as detected by FDA-approved